Pipeline

August 16, 2021

Company	Drug/Device	Medical Condition	Status
ImmVira	MVR-C5252	malignant glioma	IND approved by the FDA
YishengBio	PIKA recombinant COVID-19 vaccine	COVID-19	IND approved by the New Zealand Medicines and Medical Devices Safety Authority
Xeris Pharmaceuticals	levothyroxine	hypothyroidism	IND approved by the FDA
Ascletis Pharma	ASC40	moderate-to-severe acne	clinical trial authorized by the China National Medical Products Administration (NMPA) for a phase 2 trial
InnoCare Pharma	orelabrutinib	primary immune thrombocytopenia	IND approved by the China NMPA for a phase 2 trial
Inovio Sinovac Biotechnology	INO-4800 and CoronaVac vaccines	COVID-19	two clinical trials authorized by the China NMPA
Rezolute	RZ402	diabetic macular edema	initiation of phase 1b trial
Goldfinch Bio	GFB-887	focal segmental glomerular sclerosis	initiation of phase 2 extension trial
NRx Pharmaceuticals	BriLife vaccine	COVID-19	initiation of phase 2b trial in the nation of Georgia
Valneva	VLA2001 inactivated adjuvanted vaccine	COVID-19	phase 3 trial initiated in New Zealand
Sanofi	Nexviazyme (avalglucosidase alfa-ngpt)	late-onset Pompe disease in patients age one year and older	approved by the FDA
ZOLL Medical	remed? EL-X system	moderate-to-severe central sleep apnea	approved by the FDA
Merck Eisai	Keytruda in combination with Lemvima	advanced renal cell carcinoma	approved by the FDA